Precision Optics (NASDAQ:POCI – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.
Profitability
This table compares Precision Optics and Lucid Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precision Optics | -17.03% | -37.47% | -19.96% |
| Lucid Diagnostics | -876.72% | N/A | -116.26% |
Valuation and Earnings
This table compares Precision Optics and Lucid Diagnostics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Precision Optics | $28.94 million | 2.29 | -$5.78 million | ($0.63) | -9.60 |
| Lucid Diagnostics | $5.13 million | 38.17 | -$58.01 million | ($0.47) | -2.05 |
Precision Optics has higher revenue and earnings than Lucid Diagnostics. Precision Optics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
13.7% of Precision Optics shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 14.4% of Precision Optics shares are owned by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Precision Optics has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Precision Optics and Lucid Diagnostics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precision Optics | 1 | 0 | 0 | 0 | 1.00 |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
Lucid Diagnostics has a consensus price target of $4.19, suggesting a potential upside of 333.94%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Precision Optics.
Summary
Lucid Diagnostics beats Precision Optics on 9 of the 14 factors compared between the two stocks.
About Precision Optics
Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and illumination systems and related components primarily in the United States and the European Economic Area. It offers medical instrumentation products, including endoscopes and endocouplers, as well as other custom imaging and illumination products, such as Microprecision lenses and micro medical cameras, and 3D endoscopes for use in minimally invasive surgical procedures by hospitals and physicians. The company also provides components and assemblies for industrial and military use. It markets its products to medical device companies. The company was incorporated in 1982 and is based in Gardner, Massachusetts.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Receive News & Ratings for Precision Optics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Optics and related companies with MarketBeat.com's FREE daily email newsletter.
